Syndromic GI Panel Detects Cyclospora for Rapid Case Confirmation

S. health authorities have reported a rapid increase in cyclosporiasis since May 2026, with more than 1,600 confirmed infections and thousands of additional suspected cases under investigation. Cyclospora cayetanensis can cause prolonged diarrhea and other gastrointestinal symptoms, but routine stool culture does not detect the parasite, creating diagnostic delays. Molecular methods are therefore needed to confirm cases and guide outbreak response. 

QIAGEN’s QIAstat-Dx Gastrointestinal Panel 2 is an FDA-cleared, fully integrated syndromic assay that includes Cyclospora cayetanensis within a 16-target menu spanning bacterial, viral, and parasitic pathogens. The test delivers results in about an hour from the initial patient sample, supporting timely case confirmation during periods of heightened gastrointestinal illness. By enabling simultaneous detection of Cyclospora with other common etiologies, the panel streamlines differential diagnosis and helps laboratories prioritize appropriate follow-up testing and patient management.

For research and public health applications, QIAGEN offers the digital PCR Microbial DNA Detection Assay targeting Cyclospora cayetanensis for use with the QIAcuity digital PCR system. The assay, which is for research use only, supports highly sensitive detection that can aid surveillance activities and investigative workflows.

The company’s sequencing portfolio also includes the PulseNet-approved QIAseq FX DNA Library Prep Kit, also for research use only and compatible with any next-generation sequencer. Designed for shotgun sequencing workflows that analyze all DNA in a sample, the kit helps identify and characterize foodborne pathogens for PulseNet, the U.S. public health laboratory network that detects and investigates foodborne disease outbreaks.

“The current rise in cyclosporiasis cases highlights the need for rapid, reliable detection to support timely patient care and effective public health action. QIAGEN is ready to support laboratories and public health authorities worldwide with molecular testing technologies that help detect infections, guide investigations and strengthen responses to emerging disease threats,” said Nitin Sood, Senior Vice President and Head of Product Portfolio & Innovation at QIAGEN.